• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer

byTeddy Guo
August 16, 2022
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

RELATED REPORTS

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

Spiritual care reduces fatigue and pain among patients receiving chemotherapy

Click to read this study in The Lancet Oncology. 

Tags: advanced breast canceraromatase inhibitorBreast CancercapivasertibchemotherapyER-positive breast cancerfulvestrantmetastatic breast cancer
Previous Post

Tiotropium bromide safe and effective in treating early childhood wheezing

Next Post

PI-RADS version 2: Standardized acquisition, interpretation, and reporting of prostate MRI [Classics Series]

RelatedReports

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
StudyGraphics

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

January 31, 2023
#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

January 24, 2023
No benefit of erlotinib in combined hepatocellular carcinoma treatment
Oncology

Spiritual care reduces fatigue and pain among patients receiving chemotherapy

January 11, 2023
Palliative care consultation linked to lower deaths by failed code resuscitation
Oncology

Religious-based interventions improve illness perception in breast cancer patients

January 9, 2023
Next Post
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

PI-RADS version 2: Standardized acquisition, interpretation, and reporting of prostate MRI [Classics Series]

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

Coronary CT angiography not superior to functional testing in cardiac risk management [Classics Series]

Upadacitinib is safe and effective for treatment of non-radiographic axial spondyloarthritis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis
  • Gender-affirming hormones improve psychosocial functioning in transgender youth
  • Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options